Gabelli Maintains Their Buy Rating on Globus Medical

By Ryan Adsit

In a report issued on November 10, Jennie Tsai from Gabelli maintained a Buy rating on Globus Medical (NYSE: GMED). The company’s shares opened today at $37.22, close to its 52-week high of $37.58.

According to TipRanks.com, Tsai is a 4-star analyst with an average return of 20.5% and a 70.3% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, K2M Group Holdings, and Abbott Labs.

Currently, the analyst consensus on Globus Medical is Moderate Buy and the average price target is $35.08, representing a -5.7% downside.

In a report issued on November 8, BTIG also assigned a Buy rating to the stock with a $37 price target.

The company has a one-year high of $37.58 and a one-year low of $20.55. Currently, Globus Medical has an average volume of 709.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C.